Chondragon: A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

EORTC QOL: Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients

FaR-RMS: An overarching study for children and adults with frontline and relapsed rhabdomyosarcoma

GSK 7011618 SCOOP: Phase I Niraparib and Dostarlimab in paediatric patients with recurrent or refractory solid tumours

ICONIC: Improving outcomes through collaboration in osteosarcoma

ImmunoSARC :Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas

KINDRED ASSG: The International Sarcoma Kindred study: A global multi-site prospective cancer genetics study

PREDICT B: Predicting radiotherapy response, toxicities and quality of life related functional  outcome in soft tissue sarcoma of the extremities: a prospective observational cohort study

rEECUr: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma

RINGSIDE:  A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

SMPaeds: Stratified medicine paediatrics: genomic characterisation of relapsed paediatric cancers for diagnostics and stratified therapy

SPEARHEAD 1: A phase II single arm open-label clinical trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

TOLERANCE (EORTC-1976): A 3 arm randomized study on health-related quality of life of elderly patients with advanced soft tissue sarcoma undergoing doxorubicin alone three weekly or doxorubicin weekly or cyclophosphamide plus prednisolone treatment (TOLERANCE)

PTC596-ONC-008-LMS : A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma 

Sometimes there may be other trials open - it is always worth asking your doctor.